Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4226634 | 1.00 | TRPV1 (0.54) | TRPV1MAPK1CNR1CNR2BRD4 | |
| SCHEMBL27125516 | 0.88 | TRPV1 (0.50) | TRPV1MAPK1CNR1CNR2BRD4 | |
| SCHEMBL26962614 | 0.88 | TRPV1 (0.50) | TRPV1MAPK1CNR1CNR2BRD4 | |
| SCHEMBL599782 | 0.87 | TRPV1 (0.49) | TRPV1MAPK1CNR1CNR2BRD4 | |
| SCHEMBL20622055 | 0.87 | TRPV1 (0.49) | TRPV1MAPK1CNR1CNR2BRD4 | |
| SCHEMBL803487 | 0.87 | TRPV1 (0.49) | TRPV1MAPK1CNR1CNR2BRD4 | |
| SCHEMBL14452760 | 0.87 | TRPV1 (0.49) | TRPV1MAPK1CNR1CNR2BRD4 | |
| SCHEMBL31316828 | 0.87 | TRPV1 (0.49) | TRPV1MAPK1CNR1CNR2BRD4 | |
| SCHEMBL14277888 | 0.87 | TRPV1 (0.49) | TRPV1MAPK1CNR1CNR2BRD4 | |
| SCHEMBL13131121 | 0.84 | HTT (0.57) | TRPV1CNR1CNR2BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2096104-A1 | Organic diamines as mGluR7 modulators | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20080242698-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242698-A1 | Organic Compounds | AOC1, OTC, ODC1 | TRPV1 780/4885MAPK1 2302/4885CNR1 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.